XIENCE PRIME, which uses the same drug and biocompatible polymer as the XIENCE V Everolimus Eluting Coronary Stent System, features an enhanced stent design and a delivery system designed for greater flexibility, ideal radial strength, excellent longitudinal strength and more accurate stent placement.
Xience Prime was approved in Europe two years ago (#msg-38985789).